12:00 AM
Jul 05, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Feraheme ferumoxytol: Phase III started

AMAG began a double-blind, placebo-controlled Phase III trial to evaluate IV Feraheme in 800 patients. Takeda has rights to Feraheme in Europe, Canada, Turkey, the Commonwealth of...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >